To include your compound in the COVID-19 Resource Center, submit it here.

Alkermes Inc., Elan deal

Alkermes will acquire the Elan Drug Technologies drug delivery business from Elan in a cash and stock deal valued at about $960 million. Alkermes and EDT will combine to form

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE